Drug Profile
Research programme: neurological disorder therapeutics - Biscayne Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Insero Health
- Developer Biscayne Pharmaceuticals
- Class Alkaloids; Sesquiterpenes
- Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 05 Oct 2015 Insero Health has been acquired by Biscayne Pharmaceuticals